Bio-Techne Corporation

NasdaqGS:TECH Rapporto sulle azioni

Cap. di mercato: US$12.5b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Bio-Techne Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Bio-Techne ha un patrimonio netto totale di $2.1B e un debito totale di $319.0M, che porta il suo rapporto debito/patrimonio netto a 15.4%. Le sue attività totali e le sue passività totali sono rispettivamente $2.7B e $635.0M. L'EBIT di Bio-Techne è $207.4M rendendo il suo rapporto di copertura degli interessi 16.7. Ha liquidità e investimenti a breve termine pari a $152.9M.

Informazioni chiave

15.4%

Rapporto debito/patrimonio netto

US$319.00m

Debito

Indice di copertura degli interessi19.8x
ContantiUS$152.86m
Patrimonio nettoUS$2.07b
Totale passivitàUS$635.02m
Totale attivitàUS$2.70b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Sep 26
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Sep 11
Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

Aug 24
Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jun 09
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

May 21
Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Apr 30
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Apr 15
Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Apr 04

We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Jan 17
We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Dec 30
Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Dec 05
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Oct 10
Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Sep 22
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Sep 01
A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Jul 10
At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Jun 22
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Jun 07
With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

May 23
Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Apr 05
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Mar 21
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

Mar 06
Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jan 03
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Dec 15
We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Nov 30
Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Nov 17
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Bio-Techne releases new AVV viral titer assays

Oct 11

At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Sep 26
At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Sep 12
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Bio-Techne to seek shareholder approval for 4- for-1 stock split

Sep 01

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Aug 29
Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Bio-Techne releases Quantist Luminex data analysis software

Aug 18

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Aug 16
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $617.4M ) di TECH superano le sue passività a breve termine ( $159.4M ).

Passività a lungo termine: Le attività a breve termine di TECH ( $617.4M ) superano le sue passività a lungo termine ( $475.6M ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 8% ) di TECH è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di TECH si è ridotto da 44.4% a 15.4% negli ultimi 5 anni.

Copertura del debito: Il debito di TECH è ben coperto dal flusso di cassa operativo ( 93.7% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di TECH sono ben coperti dall'EBIT ( 16.7 x copertura).


Bilancio


Scoprire le aziende sane